Coronary Artery Disease in Patients Older than 35 and Eligible for Cardiovascular Secondary Prevention: An Italian Retrospective Observational Analysis of Healthcare Administrative Databases.
coronary artery disease
database
public health
secondary prevention
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Oct 2021
14 Oct 2021
Historique:
received:
16
09
2021
revised:
05
10
2021
accepted:
12
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
This study describes patients with coronary artery disease (CAD) who are eligible for secondary prevention and assesses their healthcare consumption and costs from the perspective of the Italian National Health Service (INHS). From the Fondazione Ricerca e Salute's database, which collects Italian healthcare administrative data, all patients aged ≥ 35, with ≥1 primary in-hospital CAD diagnosis and/or procedure on the coronary arteries, or with the specific disease exemption code, and who are suitable for long-term secondary prevention treatments, were identified in 2018 and analyzed. Demographics, comorbidities, one-year supplied drugs, hospitalizations, and costs were analyzed. From >3 million inhabitants aged ≥ 35, 46,063 (1.3%) were identified (72.1% males, mean age 70 ± 12; approximately 50% with ≥3 comorbidities). During a one-year follow-up, 96.4% were treated with ≥1 drug for secondary prevention (mainly antiplatelets and lipid lowering agents), 69.4% with ≥1 concomitant cardiovascular drug, and 95.8% with ≥1 concomitant non-cardiovascular therapy. Within one year, 30.6% of patients were hospitalized at least once, mostly due to non-cardiovascular events. Calculated by mean, the INHS paid EUR 6078 per patient. This analysis confirms the relevant burden of CAD for patients with many comorbidities and who are frequently hospitalized, and the burden on the INHS. A multidisciplinary healthcare approach is encouraged to improve patients' outcomes and reduce costs for the INHS.
Sections du résumé
BACKGROUND
BACKGROUND
This study describes patients with coronary artery disease (CAD) who are eligible for secondary prevention and assesses their healthcare consumption and costs from the perspective of the Italian National Health Service (INHS).
METHODS
METHODS
From the Fondazione Ricerca e Salute's database, which collects Italian healthcare administrative data, all patients aged ≥ 35, with ≥1 primary in-hospital CAD diagnosis and/or procedure on the coronary arteries, or with the specific disease exemption code, and who are suitable for long-term secondary prevention treatments, were identified in 2018 and analyzed. Demographics, comorbidities, one-year supplied drugs, hospitalizations, and costs were analyzed.
RESULTS
RESULTS
From >3 million inhabitants aged ≥ 35, 46,063 (1.3%) were identified (72.1% males, mean age 70 ± 12; approximately 50% with ≥3 comorbidities). During a one-year follow-up, 96.4% were treated with ≥1 drug for secondary prevention (mainly antiplatelets and lipid lowering agents), 69.4% with ≥1 concomitant cardiovascular drug, and 95.8% with ≥1 concomitant non-cardiovascular therapy. Within one year, 30.6% of patients were hospitalized at least once, mostly due to non-cardiovascular events. Calculated by mean, the INHS paid EUR 6078 per patient.
CONCLUSIONS
CONCLUSIONS
This analysis confirms the relevant burden of CAD for patients with many comorbidities and who are frequently hospitalized, and the burden on the INHS. A multidisciplinary healthcare approach is encouraged to improve patients' outcomes and reduce costs for the INHS.
Identifiants
pubmed: 34682831
pii: jcm10204708
doi: 10.3390/jcm10204708
pmc: PMC8540912
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Acarpia Farmaceutici S.r.l.
ID : None
Références
Eur Heart J. 2021 Sep 7;42(34):3227-3337
pubmed: 34458905
Circulation. 2011 Nov 29;124(22):2458-73
pubmed: 22052934
Expert Rev Clin Pharmacol. 2021 Sep;14(9):1165-1171
pubmed: 34030566
Tohoku J Exp Med. 2020;252(2):143-152
pubmed: 33028759
Eur J Clin Invest. 2021 Aug;51(8):e13551
pubmed: 33786826
Dtsch Arztebl Int. 2011 Dec;108(50):856-62
pubmed: 22259640
Environ Res. 2021 Jun;197:111154
pubmed: 33872649
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Ann Intern Med. 2020 Dec 1;173(11):895-903
pubmed: 32866419
N Engl J Med. 2015 May 7;372(19):1791-800
pubmed: 25773268
J Hypertens. 2020 Dec;38(12):2369-2377
pubmed: 32833920
Clin Drug Investig. 2021 Jul;41(7):595-604
pubmed: 34032988
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:129-40
pubmed: 22262599
Nat Rev Cardiol. 2020 Jan;17(1):9-21
pubmed: 31358978
BMC Cardiovasc Disord. 2019 Mar 28;19(1):71
pubmed: 30922234
PLoS One. 2014 May 09;9(5):e95419
pubmed: 24816637
Health Serv Res. 2004 Dec;39(6 Pt 1):1839-57
pubmed: 15533190
Int J Cardiol. 2020 Feb 1;300:20-26
pubmed: 31371116
Int J Cardiol. 2017 Nov 1;246:62-67
pubmed: 28298250
Int J Cardiol. 2016 Sep 15;219:387-93
pubmed: 27372604
N Engl J Med. 2017 Oct 5;377(14):1319-1330
pubmed: 28844192
Pharmacotherapy. 2010 Nov;30(11):1127-35
pubmed: 20973686
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175